STATUTORY RULES
1965 No. 151
__________
REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1964.*
I, THE GOVERNOR-GENERAL in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953-1964.
Dated this twenty-first
day of October, 1965.
CASEY
Governor-General.
By His Excellency’s Command,
(Signed) Ian Sinclair
Minister of State for Social Services
acting for and on behalf of the
Minister of State for Health.
________
Amendments of the National Health (Pharmaceutical Benefits) Regulations†
Commencement.
1. These Regulations shall come into operation on the first day of November, 1965.
First Schedule.
2. The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—
(a) by omitting the word—
“Calciferol.”;
(b) by omitting the words—
“Chlorcyclizine Hydrochloride.”;
(c) by omitting the word—
“Hydrochlorothiazide.”;
(d) by omitting the words—
“Mustine Hydrochloride.”;
(e) by inserting after the words—
“Nitrous Oxide.”
the words—
“Norethandrolone.
Norethandrolone Tablets.”;
(f) by inserting after the word—
“Noscapine.”
the words—
“Novobiocin Calcium.
Novobiocin Sodium.”;
*Notified in the Commonwealth Gazette on 28 October, 1965.
† Statutory Rules 1960, No. 17, as amended to date. For previous amendments of the National Health (Pharmaceutical Benefits) Regulations, see footnote † to Statutory Rules 1965, No. 51 and see also Statutory Rules 1965, No. 51.
11409/65.—Price 2s. 6d. (25c) 10/5.10.1965
(g) by omitting the words—
“Piperazine Phosphate”; and
(h) by inserting after the words—
“Undecenoic Acid.”
the words—
“Vancomycin Hydrochloride.
Vancomycin Injection.”.
3. The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended—
Second Schedule.
(a) by omitting the item relating to the pharmaceutical benefit
“Adrenaline Acid Tartrate, B.P.”;
(b) by omitting the item relating to the pharmaceutical benefit
“Aluminium Hydroxide Gel Dried, B.P.”;
(c) by inserting after the item relating to the pharmaceutical benefit
“Betamethasone Phosphate” the following item:—
“ Calciferol........................ | —”; |
(d) by inserting after the item relating to the pharmaceutical benefit
“Erythromycin Oral Suspensions” the following item:—
“Erythromycin Paediatric Drops.......... | —”; |
(e) by omitting the item relating to the pharmaceutical benefit
“Ferrous Gluconate, B.P.”;
(f) by inserting after the item relating to the pharmaceutical benefit
“Framycetin Sulphate” the following item:—
“Fusidic Acid (Diethanolamine Salt)....... | —”; |
(g) by omitting the item relating to the pharmaceutical benefit
“Magnesium Bicarbonate Solution, B.P. 1948”;
(h) by inserting after the item relating to the pharmaceutical benefit
“Mepyramine Maleate, B.P.” the following item:—
“Methacycline...................... | —”; |
(i) by omitting the item relating to the pharmaceutical benefit
“Paracetamol, B.P.”;
(j) by omitting the item relating to the pharmaceutical benefit
“Sulphadimethoxine, B.P.C.”;
(k) by omitting the item relating to the pharmaceutical benefit
“Sulphamethoxydiazine”;
(l) by omitting the item relating to the pharmaceutical benefit
“Sulphamethoxypyridazine N-Acetyl”; and
(m) by inserting after the item Telating to the pharmaceutical benefit
“Surgical Cement” the following item:—
“Surgical Cement Solvent.............. | —”. |
Third and Fifth Schedules.
4. The Third and Fifth Schedules to the National Health (Pharmaceutical Benefits) Regulations are repealed and the following Schedules inserted in their stead:—
THIRD SCHEDULE
Regulation 11
Drugs and Medicinal Preparations Additional to the Drugs and Medicinal Preparations in the British Pharmacopoeia
Acetazolamide Sodium. Acetohexamide. Acidified Golden Syrup, A.P.F. 1955. Acriflavine, B.P.C. Acrylic Resin. Adrenaline Hydrochloride. Adrenaline Mucate. Agar B.P.C. 1954. Alkavervir. Aloin B.P.C. Almond Oil Volatile Bitter, B.P.C. 1959. Aloxidone. Aluminium Acetate Solution, B.P.C. Aluminium Hydroxide Mixture, A.P.F. Aluminium Hydroxide Mixture, A.P.F. 1955. Aluminium Sodium Polyhydroxy Mon-ocarbonate Hexitol Complex. Aluminium Sodium Silicate. Aluminium Powder, B.P.C. Amaranth Solution, A.P.F. Amaranth Solution, Compound, A.P.F. Amaranth Solution, B.P.C. Aminocaproic Acid. Amitriptyline Hydrochloride. Ammonia Aromatic Spirit, B.P.C. Ammonia Solution Strong, B.P.C. Ammonium Bicarbonate, B.P.C. Ammonium Bromide, B.P.C. Amphotericin B. Ampicillin. Antazoline Methanesulphonatc, B.P.C. Antazoline Sulphate. Attapulgite. Aurothioglucose. Azathioprine. Beclamide. Beeswax, Yellow, B.P.C. Belladonna Suppository, B.P. 1948. Benedict’s Solution, A.P.F. Benzalkonium Chloride. Benzoin, B.P.C. Benzoinated Lard, B.P.C. 1954. Benzoin Compound Tincture, B.P.C. Benzoin Tincture, B.P.C. Benzylpenicillin in Oil. Bephenium Hydroxynaphthoate, B.P.C. Betamethasone. Betamethasone Disodium Phosphate. Betamethasone Phosphate. Bethanidine Sulphate. Bismuth Subgallate, B.P.C. Bretylium Tosylate. Brown Snake Antivenene. Buchu Concentrated Infusion, B.P.C. 1954. Butabarbital Sodium. | Butyl Aminobenzoate, B.P. 1953. Cade Oil, B.P.C. Caffeine and Sodium Benzoate, B.P.C. 1954. Caffeine Citrate, B.P.C. 1959. Cajuput Spirit, B.P. 1948. Calamine Cream, A.P.F. 1955. Calcium Aurothiomalate. Calcium Di-Oxytetracycline. Calcium Gluconogalactogluconate. Calcium Lactobionate. Calcium Phosphate, B.P.C. Calumba, Concentrated Infusion, B.P. 1948. Calumba Tincture, B.P. 1948. Capsicum Ointment, B.P.C. Capsicum Tincture, B.P.C. Carbamazepine. Carbarsone, B.P.C. Carbinoxamine Maleate. Cardamom Aromatic Tincture, B.P.C. Catechu Tincture, B.P.C. Cetomacrogol Emulsifying Wax, B.P.C. Cetyl Alcohol Compound. Chloramine, B.P.C. Chloramphenicol Palmitate, B.P.C. Chloramphenicol Stearate. Chloramphenicol Succinate. Chlorazanil Hydrochloride. Chlorhexidine Diacetate. Chlorhexidine Gluconate. Chlorobenzol Disulphonamide. Chlorotrianisene, B.P.C. Chlorthalidone, B.P.C. Choline Theophyllinate, B.P.C. Cinnamon Spirit, B.P.C. 1949. Cinnamon Water, Concentrated, B.P.C. Clemizole Hydrochloride. Clemizole Tannate. Clopamide. Clove, Concentrated Infusion, B.P.C. 1954. Cloxacillin Sodium. Coal Tar, B.P.C. Cochineal Tincture, B.P. 1948. Coconut Oil, B.P.C. 1949. Codeine, B.P.C. 1954. Copper Sulphate, B.P.C. Creosote, B.P.C. 1959. Cudbear Tincture, A.P.F. 1947. Curd Soap, B.P.C. Cyclopenthiazide. Cyclophosphamide. Cyclothiazide. Cycrimine Hydrochloride. Cymogran. Cyproheptadine Hydrochloride. Death Adder Antivenene. |
Third Schedule—continued
Demecarium Bromide. Deoxycortone Glucoside. Desferrioxamine. Deslanoside. Dexamethasone Sodium Phosphate. Dexchlorpheniramine Maleate. Dextran. Dextriferron. Dicyclomine Hydrochloride, B.P.C. Digitalis Tincture, B.P.C. 1959. Dihydroergotamine Methanesulphonate. Dihydromorphinone Hydrochloride, B.P.C. 1949. Dihydrostreptomycin Sulphate, B.P. 1958. Dihydrotachysterol. Dimethicone, B.P.C. Diphenylpyraline Hydrochloride. Dipyridamole. Disodium Stilboestrol Diphosphate. Dithiazanine Iodide. Dyflos, B.P.C. Ecothiopate Iodide. Entsufon. Ephedrine, B.P.C. Ergot, Liquid Extract, B.P. 1914. Erythromycin Ethyl Succinate. Erythromycin Glucoheptonate. Erythromycin Lactobionate. Erythromycin Stearate. Ethanolamine, B.P.C. Ethanolamine Oleate. Ether Nitrous Spirit, B.P.C. 1959. Ethionamide. Ethosuximide. Ethoxzolamide. Ethyl Biscoumacetate, B.P.C. Ethylidene Dicoumarin. Ethylnoradrenaline Hydrochloride. Ethyloestrenol. Eucalyptol, B.P.C. Extract of Ox Bile, B.P. 1948. Ferric Hydroxide. Ferrous Aminoacetosulphate. Ferrous Carbonate Saccharated, B.P.C. 1959. Ferrous Phosphate Compound Syrup, B.P.C. Ferrous Phosphate with Quinine and Strychnine Syrup, B.P.C. Ferrous Succinate. Folinic Acid. Framycetin Sulphate. Frusemide. Fusidic Acid, Diethanolamine Salt. Fusidic Acid, Sodium Salt. Galactomin. Gall and Opium Ointment, B.P.C. Gelsemium Tincture, B.P.C. Glucagon Hydrochloride. Glucose Indicator. Glycerophosphate Compound Syrup, A.P.F. Glycopyrronium Bromide. Goats Milk, dehydrated. Gramicidin.
| Hamamelis Dry Extract, B.P.C. Hamamelis Liquid Extract, B.P.C. Heparin Retard. Hexocyclium Methylsulphate. Honey, Purified, B.P.C. Hydrargaphen. Hydrocyanic Acid, Dilute, B.P.C. 1954. Hydroxybenzoate Compound Powder, A.P.F. Hydroxyprogesterone Caproate. Hyoscine Methobromide. Hypophosphorous Acid, Dilute, B.P.C. Idoxuridine. Indomethacin. Insulin Injection, specially purified. Insulin Isophane Injection, specially purified. Insulin Injection, Special P (Pig). Iodochlorhydroxyquinoline. Iodoform, B.P.C. 1954. Iron Aminoates. Iron Dextran. Iron Oxide Saccharated. Iron Sorbitol Complex. Isoprenaline Hydrochloride. Isopropamide Iodide. Isothipendyl Hydrochloride, B.P.C. Kanamycin Sulphate, B.P.C. Kitasamycin. Lanatoside-C. Lavender Spike Oil, B.P.C. Lemon Tincture, B.P. 1958. Lipopancreatin. Lissapol. Lobelia Ethereal Tincture, B.P.C. Lofenalac. Lypressin. Magenta, B.P.C. Magnesium Chloride. Magnesium Hydroxide, B.P.C. Mebhydrolin Napadisylate, B.P.C. Medroxyprogesterone Acetate. Mercaptomerin Sodium. Mestanolone. Metaraminol Bitartrate. Metformin Hydrochloride. Methacycline. Methazolamide. Methdilazine Hydrochloride. Methenamine Mandelate. Methenolone Acetate. Methotrexate. Methoxamine Hydrochloride, B.P.C. Methsuximide. Methyclothiazide. Methyldopa. Methyl Glucamine. Methylphenobarbitone, B.P.C. Methylprednisolone Acetate. Metronidazole, B.P.C. Minafen. Morphine Tartrate. Myrrh Gum, Powdered, B.P.C. Myrrh Tincture, B.P.C. Nalidixic Acid.
|
Third Schedule—continued
Nandrolone Decanoate. Niclosamide. Nicotinyl Alcohol Tartrate. Nicoumalone. Nitromin. Nux Vomica, Dry Extract, B.P.C. Oestradiol Dipropionate, B.P.C. 1954. Oestrone, B.P.C. 1954. Oily Ophthalmic Vehicle, A.P.F. 1955. Orange Peel Compound, Concentrated Infusion, B.P.C. 1954. Orange Peel, Concentrated Infusion, B.P.C. Orciprenaline Sulphate. Oxycodone Pectinate. Oxymel, B.P.C. Oxymel of Squill, B.P.C. Oxymesterone. Oxyphencyclimine Hydrochloride. Oxyphenonium Bromide. Oxytocin. Pancreatin Enzyme, U.S.N.F. XI. Papaveretum, B.P.C. Para-Aminosalicylic Acid. Paraben Ophthalmic Phosphate Buffer, A.P.F. 1955. Paraben Ophthalmic Vehicle, A.P.F. 1955. Paraffin Liquid Light, B.P.C. Paramethasone Acetate. Pargyline Hydrochloride. Pectin. d-Penicillamine Hydrochloride, B.P.C. Penicillinase. Penicillin, Benethamine, B.P.C. Pentaerythritol Tetranitrate, diluted, B.P.C. Penthienate Methobromide. Pertussis Vaccine (Haemagglutinin Aluminium Phosphate Adsorbed). Peru Balsam, B.P.C. Phenazone, B.P.C. Phenazopyridine Hydrochloride. Phenethicillin Potassium. Phenformin Hydrochloride. Pheniramine Maleate. Pheniramine Para-Aminosalicylate. Phenol Ointment, B.P. 1948. Phenoxymethylpenicillin, Benzathine. Phenoxymethylpenicillin, Hydrabamine. Phensuximide. Phenytoin. Phthalylsulphacetamide. Physostigmine, B.P.C. Pipenzolate Methobromide. Pituitary (Posterior Lobe) Powdered, B.P.C. Polythiazide. Potable Water. Potassium Chlorate, B.P.C. Potassium, Effervescent Tablets. Prednisolone Sodium Hemisuccinate. Prednisolone Sodium Hemisulphate. Prednisolone Sodium Phosphate, B.P.C. Prednisolone Tertiary Butyl Acetate. Protoveratrine A. Pumilio Pine Oil, B.P.C. | Pyrazinamide. Pyridine Aldoxime Methiodide. Quillaia Tincture, B.P.C. Quinethazone. Raspberry Syrup, B.P.C. Rauwolfia Alkaloids. Red Back Spider Antivenene. Rolitetracycline. Rosemary Oil, B.P.C. Salicylamide. Senega, Concentrated Infusion, B.P.C. Senna Compound Mixture, B.P.C. 1959. Senna, Concentrated Infusion, B.P.C. 1959. Senna Fruit Extract (Standardised). Siberian Fir Oil, B.P.C. 1949. Silver Protein, B.P.C. Silver Protein Mild, B.P.C. Sobee. Sodium Carbonate Anhydrous, B.P.C. Sodium Edetate, B.P.C. Sodium Folate. Sodium Lactate. Sodium Nitrite, B.P.C. Sodium Potassium Tartrate, B.P.C. Sodium Tauroglycocholate, B.P.C. 1954. Spearmint Oil, B.P.C. Spiramycin. Spironolactone, B.P.C. Squill Tincture, B.P.C. Stanolone. Stanozolol. Stearic Acid, B.P.C. Storax, Prepared, B.P.C. Strophanthus Tincture, B.P. 1948. Strychnine, B.P.C. 1959. Sulphacetamide, B.P.C. Sulphadiazine Sodium, B.P.C. Sulphadimethoxine, B.P.C. Sulphaguanidine, B.P.C. Sulphamerazine, B.P. 1958. Sulphamethoxydiazine. Sulphaphenazole, B.P.C. Sulphapyridine, B.P.C. 1959. Sulphasalazine. Sulphathiazole, B.P.C. Sulphinpyrazone, B.P.C. Sulphurated Potash, B.P.C. Sulphuric Acid, Dilute, B.P.C. Sulphur Sublimed, B.P.C. Sultiame. Surgical Cement. Surgical Cement Solvent. Sustanon. Syrup Glucose Liquid, B.P.C. Tacrine. Taipan Antivenene. Tar Ointment, B.P.C. 1959. Tartrazine, B.P.C. 1954. Testosterone Oenanthate. Tetanus Immune Globulin (Human). Tetracycline. Thenalidine. Thenalidine Tartrate. Theobromine, B.P.C.
|
Third Schedule—continued
Theobromine and Sodium Salicylate, B.P. 1953. Theophylline Ethanoate of Piperazine. Thiethylperazine. Thioridazine. Thiotepa. Thyrotrophin. Tiger Snake Antivenene. Titanium Dioxide, B.P.C. Tolu Tincture, B.P.C. 1959. Tragacanth (Gum Karaya). Tretamine. Triamcinolone, B.P.C. Triamterene. Tricyclamol Chloride. Tridihexethyl Chloride. Triethanolamine, B.P.C | Trimeprazine Tartrate, B.P.C. Trimustine Hydrochloride. Trinitrophenol, B.P.C. 1959. Triprolidine Hydrochloride, B.P.C. Trolnitrate Phosphate. Vadrine. Valerian Ammoniated Tincture, B.P.C. Vanillin. Vasopressin Tannate. Velactin. Vinblastine Sulphate. Vincristine Sulphate. Vinegar of Squill, B.P.C. Viomycin Pantothenate. Viprynium Embonate. Vitamin A. Vitamin D.
|
________________
FIFTH SCHEDULE
Regulation 14
Pharmaceutical Benefits the Prescribing of Which is Subject to Conditions and Restrictions
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
Acetylsalicylic Acid Tablets, B.P....... |
|
Soluble Acetylsalicylic Acid Tablets, B.P. |
|
Compound Acetylsalicylic Acid Tablets, A.P.F. | Any disease or condition in a pensioner |
Compound Acetylsalicylic Acid Tablets, B.P.C. |
|
Soluble Compound Acetylsalicylic Acid Tablets |
|
Acrylic Resin................... | Ileostomy or colostomy conditions |
Alkavervir..................... | Hypertensive crises |
Aminocaproic Acid............... | Any disease or condition in a patient receiving treatment in or at an approved hospital. |
Amitriptyline Hydrochloride......... | Any disease or condition in a patient receiving treatment in or at an approved hospital. |
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine Hydrochloride, Thioridazine Hydrochloride, Amitriptyline Hydrochloride or Imipramine Hydrochloride |
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
Amphotericin B.............. | Systemic fungal infection |
Ampicillin Capsules............ | With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Ampicillin is the only appropriate antibiotic |
Ampicillin Injections........... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Ampicillin Tablets............. | |
Aneurine Hydrochloride Tablets, B.P. | Any disease or condition in a pensioner |
Ascorbic Acid Tablets, B.P........ | |
Azathioprine................. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Beclamide.................. | |
Bemegride Injection, B.P......... | As an antidote to barbiturate and other hypnotic poisons |
Betamethasone Tablets.......... | With the written authority of the Director-General, a disease or condition specified in this column in relation to Prednisolone Tablets |
Betamethasone Disodium Phos-phate Injection | Intra-articular use |
Bethanidine Sulphate........... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Busulphan Tablets, B.P.......... | Leukaemia |
Calciferol Tablets, B.P........... | Any disease or condition in a pensioner With the written authority of the Director-General— |
Calciferol, B.P................ | Hypoparathyroidism |
| Chronic hypoparathyroid tetany |
| Vitamin D-resistant rickets |
Calcium Aminosalicylate........ | Tuberculosis |
Calcium Gluconogalactogluconate Effervescent Tablets | Hypoparathyroidism |
Caramiphen Tablets, B.P......... | Parkinsonism |
Carbamazepine............... | Epilepsy |
| Trigeminal neuralgia |
Chlorambucil Tablets, B.P........ | Malignant lymphoma and related conditions |
Chloramine Deodorant Tablets and Powder | Ileostomy or colostomy conditions |
Chloramphenicol Capsules, B.P.... | Bacterial meningitis |
| Haemophilus influenzae infections |
| Intra-ocular infections |
| Rickettsial infections |
| Salmonella septicaemia |
| Typhoid and paratyphoid |
| Other serious infections sensitive only to Chloramphenicol |
Chloramphenicol Injections....... | A disease or condition specified in this column in relation to Chloramphenicol Capsules |
Chloramphenicol Tablets........ | |
Chloramphenicol Oral Suspension.. | |
Chlorotrianisene Tablets......... | Carcinoma of the prostate |
Chlorpromazine Hydrochloride.... | Any disease or condition in a pensioner |
| Any disease or condition in a patient receiving treatment in or at an approved hospital |
| With the written authority of the Director-General— |
| Late-stage malignancy |
| Radiation sickness |
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine Hydrochloride, Thioridazine Hydrochloride, Amitriptyline Hydrochloride or Imipramine Hydrochloride |
Chlortetracycline Capsules, B.P.... | Brucellosis |
| Herpes zoster ophthalmicus |
| Intestinal amoebiasis |
| Leptospirosis |
| Lymphogranuloma venereum |
| Psittacosis |
| Rickettsial infections |
| Any bacterial infections or actinomycosis or trachoma where these cannot be treated safely and effectively by sulphonamides or penicillins. |
| Pre-operative and post-operative therapy where there are reasonable grounds for believing that infection may occur |
Chlortetracycline Hydrochloride Granules | A disease or condition specified in this column in relation to Chlortetracycline Capsules |
Choline Theophyllinate.......... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Cloxacillin Sodium............ | |
Compound Codeine Tablets, B.P.... |
|
Compound Codeine Soluble Tablets, B.P. |
|
Codeine Phosphate with Acetylsalicylic Acid Soluble Tablets |
|
Codeine Phosphate with Acetylsalicylic Acid Tablets | Any disease or condition in a pensioner |
Codeine Phosphate with Acetylsalicylic Acid and Phenacetin Tablets |
|
Codeine Phosphate with Acetylsalicylic Acid, Phenacetin and Caffeine Tablets |
|
Cod Liver Oil Emulsion......... | Any disease or condition in a child under the age of twelve years or in a pensioner |
| With the written authority of the Director-General— |
Corticotrophin Injection, B.P...... | A disease or condition specified in this column in relation to Cortisone Injection |
Corticotrophin Gelatin Injection, B.P. | Hypsarrhythmia |
Corticotrophin Zinc Hydroxide Injection, B.P. | Salaam convulsions |
| The prevention of side effects of corticosteroid therapy |
Cortisone Injection, B.P......... | With the written authority of the Director-General— |
| Anaemia, acquired hacmolytic |
| Addison’s disease |
| Adrenocortical hypoplasia |
| Adrenalectomy, total |
| Adrenogenital syndrome |
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
Cortisone Injection, B.P.-continued | Agranulocytosis |
| Behcet’s syndrome |
| Cranial arteritis |
| Cushing’s syndrome, including hyperadrenocorticalism |
| Dematitis, acute exfoliative |
| Dermatomyositis |
| Encephalomyelitis |
| Encephalomyelitis, acute disseminated |
| Guillain-Barré syndrome |
| Hamman-Rich syndrome—diffuse interstitial pulmonary fibrosis |
| Hansen’s disease |
| Hepatitis, progressive or continuing, proven by biopsy or biochemistry |
| Hodgkin’s disease |
| Idiopathic hypercalcaemia |
| Inflammatory conditions of the uveal tract and retina |
| Keratoplasty |
| Leucine-sensitive hypoglycaemia |
| Leukaemia |
| Lymphosarcoma and follicular lymphoma |
| Metastatic breast cancer |
| Mycosis fungoidcs |
| Nephrosis or nephrotic syndrome |
| Neuromyelitis optica |
| Optic neuritis following removal of tumor of the brain |
| Panhypopituitarism |
| Pemphigus |
| Periarteritis nodosa |
| Progressive transverse myelitis |
| Pseudohermaphroditism |
| Purpura, Henoch’s |
| Purpura, thrombocytopenic |
| Regional ileitis (Crohn’s disease) |
| Reticulum cell sarcoma |
| Rheumatic carditis, acute |
| Sarcoidosis |
| Scleroderma |
| Severe reactions of the skin and mucosa following X-ray therapy |
| Splenic neutropenia |
| Status asthmaticus |
| Steroid therapy prior to operation in patients under steroid therapy |
| Stevens-Johnson syndrome |
| Still’s disease in a child under the age of sixteen years |
| Sympathetic ophthalmitis |
| Systemic lupus erythematosus |
| Temporal arteritis |
| Tropical and non-tropical sprue and all forms of malabsorption associated with those diseases |
| Type II Nephritis |
| Ulcerative colitis proven by sigmoidoscopy or radiological report |
Cortisone Tablets, B.P........... | With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection |
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
Cyanocobalamin Injection, B.P. (other than 1,000 microgram strength) | Established megalocytic anaemia |
Cyanocobalamin Injection, B.P. (1,000 microgram strength) | Neuroblastoma |
Subacute combined degeneration of the cord | |
Cymogran.................. | With the written authority of the Director-General, phenylketonuria |
Cycloserine, B.P............... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Cycloserine Capsules, B.P........ | |
Dapsone Tablets, B.P........... | Hansen’s disease |
Demethylchlortetracycline Capsules, B.P. | A disease or condition specified in this column in relation to Chlortetracycline Capsules, except herpes zoster ophthalmicus |
Pemethylchlortetracycline Hyd-rochloride Oral Paediatric Drops and Oral Suspension | |
Deodorant Detergent Solution (Lis-sapol with Spearmint Oil and Cetrimide) | Ileostomy or colostomy conditions |
Deoxycortone Aqueous Injections |
|
Deoxycortone Acetate Injection, B.P. |
|
Deoxycortone Trimethylacetate Injection, B.P. | Addison’s disease Adrenalectomy, total |
Deoxycortone Acetate Implants, B.P. |
|
Deoxycortone Acetate Tablets..... |
|
Desferrioxamine.............. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Dexamethasone Tablets, B.P...... | With the written authority of the Director-General, a disease or condition specified in this column in relation to Prednisolone Tablets |
Dexamethasone Sodium Phosphate Injections | Intra-articular use |
Dienoestrol Cream............ | Any disease or condition in a pensioner |
Dienoestrol Tablets, B.P......... | Carcinoma of the prostate |
| Mammary carcinoma |
| Any disease or condition in a pensioner |
Dihydrostreptomycin Sulphate Injection | As an alternative to Streptomycin Sulphate in the case of a person who is being treated for a disease or condition specified in this column in relation to Streptomycin Sulphate and who is allergic to Streptomycin Sulphate |
Dihydrotachysterol............ | Parathyroid deficiency |
Diiodohydroxyquinoline Vaginal Tablet | Trichomonal or monilial vaginitis |
Diiodohydroxyquinoline Effervescent Gynaecological Pessary | |
Diloxanide Furoate Tablets, B.P.... | Amoebic dysentery |
Dimethicone................ | Ileostomy or colostomy conditions |
Disodium Stilboestrol Diphosphate | Carcinoma of the prostate |
Dithiazanine Iodide............ | Infestations of Trichuris trichiura or Strongyloides stercoralis |
Ditophal................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Erythromycin................ | Staphylococcal septicaemia or pneumonia |
| Any gram-positive bacterial infections where these cannot be treated safely and effectively by sulphonamides or penicillins |
Ethinyloestradiol Tablets, B.P...... | Turner’s syndrome |
| Pre-menopausal castration syndrome |
| Any disease or condition in a pensioner |
Ethionamide................. | Tuberculosis |
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
Ethisterone Tablets, B.P......... | Turner’s syndrome |
Ethyloestrenol............... | With the written authority of the Director-General, intermittent use for steroid-induced osteoporosis |
Fludrocortisone Tablets, B.P...... | Addison’s disease |
| Adrenocortical hypoplasia |
Fluoxymesterone Tablets, B.P..... | Castration syndrome (male and female) |
| Mammary carcinoma |
| With the written authority of the Director-General, intermittent use for steroid-induced osteoporosis |
Folic Acid Injection............ | Macrocytic anaemia |
Folic Acid Tablets, B.P.......... | Sprue or the sprue-like syndrome |
Folinic Acid................. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Framycetin Sulphate Tablets...... | Bowel sterilization preparatory to major surgery. |
Fusidic Acid (Sodium Salt or Diethanolamine Salt) | With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Fusidic Acid (Sodium Salt or Diethanolamine Salt) is the only appropriate antibiotic. |
Galactomin................. | With the written authority of the Director-General, galactosaemia |
Goats Milk, dehydrated......... | With the written authority of the Director-General, cows milk allergy in children under the age of four years |
Griseofulvin Tablets, B.P........ | With the written authority of the Director-General, for use in severe tinea infections due to Microsporum, Trichophyton or Epidermophyton species which have been proven by laboratory examination |
Halibut Liver Oil Capsules....... | Any disease or condition in a pensioner |
Hexachlorophane with Entsufon.... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Hexachlorophane with Lissapol.... | |
Hexachlorophane in Soap Solution | |
Hydrocortisone Injection......... | With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection |
Hydrocortisone Acetate Injection, B.P. | Intra-articular use |
Hydrocortisone Sodium Succinate Injection | Acute adrenal failure due to medical or surgical crises |
| Stevens-Johnson syndrome |
Hydrocortisone Sodium Succinate Soluble Tablet | With the written authority of the Director-General, ulcerative colitis proven by sigmoidoscopy or radiological report |
Hydroxocobalamin Injection, B.P. (100 microgram strength) | Established megalocytic anaemia |
Hydroxocobalamin Injection, B.P. (1,000 microgram strength) | Neuroblastoma |
| Sub-acute combined degeneration of the cord |
Hydroxyprogesterone Caproate.... | Habitual abortion |
Imipramine Tablets, B.P. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
Imipramine Tablets, B.P.—continued | The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine Hydrochloride, Thioridazine Hydrochloride, Amitriptyline Hydrochloride or Imipramine Hydrochloride |
Indomethacin................ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Isoniazid Tablets, B.P........... | Tuberculosis |
Kanamycin Sulphate........... | With the written authority of the Director-General, infections where positive bacteriological evidence confirms that Kanamycin Sulphate is the only appropriate antibiotic |
Kitasamycin................. | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Levorphanol Tartrate........... | Obstetrical use |
| Severe intractable pain |
Liothyronine Tablets, B.P........ | Myxoedema |
| Myxoedema coma |
Lipopancreatin............... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Lofenalac | With the written authority of the Director-General, phenylketonuria |
Medroxyprogesterone Acetate..... | Endometrial carcinoma |
Mercaptopurine Tablets, B.P...... | Allergic angiitis |
| Leukaemia |
| Lupus erythematosus |
| Periarteritis |
Mestanolone................. | Mammary carcinoma |
| With the written authority of the Director-General, intermittent use for steroid-induced osteoporosis |
Methacycline................ | A disease or condition specified in this column in relation to Chlortetracycline Capsules, except herpes zoster ophthalmicus |
Methandienone Tablets, B.P...... | With the written authority of the Director-General, intermittent use for steroid-induced osteoporosis |
Methenolone Acetate........... | |
Methicillin Sodium............ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Methicillin Injection, B.P........ | |
Methotrexate Tablets........... | Leukaemia and neoplastic disease |
Methotrexate Injections......... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Minafen.................... | With the written authority of the Director-General, phenylketonuria |
Morphine Sulphate, B.P. with Tacrine Tablets | Severe intractable pain |
Mustine Hydrochloride Injection | Malignant lymphoma and related conditions |
Nalidixic Acid | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
Nandrolone Phenylpropionate Injection, B.P. | With the written authority of the Director-General, intermittent use for steroid-induced osteoporosis |
Nandrolone Decanoate.......... | |
Neomycin Sulphate Tablets....... | Bowel sterilization preparatory to major surgery |
Nicotinic Acid Tablets, B.P....... | Any disease or condition in a pensioner |
Nitrofurantoin Tablets, B.P....... | Urinary tract infections |
Nitrofurantoin Oral Suspension.... | |
Nitromin................... | Malignant lymphoma and related conditions |
Nystatin................... | Proven monilia infections |
Orciprenaline Sulphate Injection... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Orciprenaline Sulphate Solution for Inhalation | |
Oxycodone Pectinate........... | Late-stage malignancy |
Oxymesterone............... | With the written authority of the Director-General, intermittent use for steroid-induced osteoporosis. |
Oxytetracycline Hydrochloride Capsules | A disease or condition specified in this column in relation to Chlortetracycline Capsules except herpes zoster ophthalmicus |
Oxytetracycline Tablets, B.P...... | |
Oxytetracycline Hydrochloride Injections | |
Calcium di-Oxytetracycline Oral Suspension | |
Calcium di-Oxytetracycline Paediatric Drops | |
Oxytocin Nasal Spray.......... | Induction of labour |
Pancreatin, B.P............... | Fibrocystic disease |
Pancreatin Enzyme U.S.N.F. XI.... | Pancreatico-duodenectomy |
| Pancreatic steatorrhoea |
Para-Aminosalicylic Acid........ | Tuberculosis |
Paracetamol Suspension......... | Any disease or condition in a pensioner. |
Paracetamol Tablets, B.P......... | |
Paramethasone Acetate......... | With the written authority of the Director-General, a disease or condition specified in this column in relation to Cortisone Injection |
Paraffin Liquid Emulsion........ | Any disease or condition in a pensioner |
Paraffin Liquid Emulsion with Phenolphthalein | |
Pargyline Hydrochloride......... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Penicillamine................ | With the written authority of the Director-General, Wilson’s disease (hepatolenticular degeneration) |
Peritoneal Dialysis Solution...... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Pethidine Hydrochloride with Levallorphan Tartrate | Obstetrical use |
Benzylpenicillin with Streptomycin Sulphate | Endocarditis due to Streptococcus faecalis or Streptococcus viridans |
Benzylpenicillin with Procaine Penicillin and Streptomycin Sulphate | |
Phenacetin with Codeine Phosphate and Pentobarbitone Sodium | Any disease or condition in a pensioner |
Phytomenadione Injection, B.P..... | Antidote to anticoagulants |
Pituitary, Posterior Lobe, Insufflation | Diabetes insipidus |
Polymyxin B. Sulphate Injection... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
Prednisolone Sodium Phosphate Retention Enema | With the written authority of the Director-General, ulcerative colitis proven by sigmoidoscopy or radiological report |
Prednisolone Tablets, B.P......... | With the written authority of the Director-General— |
| Nodular non-suppurative panniculitis (Christian-Weber disease) |
| A disease or condition specified in this column in relation to Cortisone Injection except total adrenalectomy, Addison’s disease or adrenocortical hypoplasia |
Prednisolone Acetate Injection..... |
|
Prednisolone Methyl Acetate Injections |
|
Prednisolone Tertiary Butyl Acetate Injections | Intra-articular use |
Prednisolone Trimethylacetate Injections |
|
Methylprednisolone Tablets, B.P.... |
|
Methylprednisolone Capsules...... | With the written authority of the Director-General, a disease or condition specified in this column in relation to Prednisolone Tablets |
Prednisolone with Magnesium Trisilicate and Dried Aluminium Hydroxide Gel | |
Prednisolone Sodium Hemisuccinate | With the written authority of the Director-General, medical or surgical crises |
Prednisone Tablets, B.P.......... | With the written authority of the Director General, a disease or condition specified in this column in relation to Prednisolone Tablets |
Prednisone with Magnesium Trisilicate and Dried Aluminium Hydroxide Gel | |
Progesterone................. | Habitual abortion |
Protoveratrine A.............. | Hypertensive crises |
Pyrazinamide................ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Pyridostigmine Injection, B.P...... | Myasthenia gravis |
Pyridostigmine Tablets, B.P....... | |
Pyridoxine Hydrochloride Tablets | Peripheral neuritis due to isoniazid therapy |
| Radiation sickness |
Riboflavine Tablets............ | Any disease or condition in a pensioner |
Senna Fruit Extract (Standardised) | |
Sobee..................... | With the written authority of the Director-General— |
| Galactosaemia |
| Lactose intolerance |
| Milk allergy in children under the age of four years |
Sodium Aminosalicylate Tablets B.P. | Tuberculosis |
Sodium Aminosalicylate Injection | |
Sodium Aminosalicylate Cachets | |
Sodium Aminosalicylate Granules | |
Sodium Folate................ | Macrocytic anaemia |
Sprue or the sprue-like syndrome | |
Spiramycin.................. | A disease or condition specified in this column in relation to Erythromycin |
Spironolactone............... | With the written authority of the Director-General, to supplement other diuretics when these have proved inadequate. |
Stanolone................... | Mammary carcinoma |
| With the written authority of the Director-General, intermittent use for steroid-induced osteoporosis |
Stanozolol.................. | With the written authority of the Director-General, intermittent use for steroid-induced osteoporosis |
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
Stilboestrol Injection............ | Carcinoma of the prostate |
Stilboestrol Tablets, B.P.......... | Mammary carcinoma |
| Any disease or condition in a pensioner |
Streptomycin Sulphate Injections.... | Bacillary dysentery that is resistant to the Sulphonamides |
| Brucellosis |
| Chancroid |
| Endocarditis due to Streptococcus faccalis or Streptococcus viridans |
| Friedlander bacillus infections |
| Haemophilus influenzae infections |
| Plague |
| Pseudomonas pyocyanea infections |
| Rat-bite fever (Streptobacillus moniliformis) |
| Salmonella infections |
| Surgical conditions of the bowel (pre-operative and post-operative) |
| Surgical conditions of the thoracic organs |
| Tuberculosis |
| Tularaemia |
| Urinary tract infections that are resistant to the Sulphonamides |
Sulphasalazine................ | Ulcerative colitis |
Sultiame.................... | For use where other anticonvulsants have failed |
Surgical Cement............... | Ileostomy or colostomy conditions |
Surgical Cement Solvent......... | |
Sustanon.................... |
|
Testosterone Implants, B.P........ | Castration syndrome (male and female) |
Testosterone Oenanthate......... | Klinefelter Reifenstein Albright syndrome |
Testosterone Propionate Injection, B.P. | Mammary carcinoma |
Methyltestosterone Tablets, B.P..... |
|
Methyltestosterone, B.P.......... |
|
Tetanus Immune Globulin (Human) | With the written authority of the Director-General, where patients are known to be sensitive to horse serum and cattle serum. |
Tetracycline Capsules, B.P........ |
|
Tetracycline Tablets, B.P......... |
|
Tetracycline Injections.......... |
|
Tetracycline Hydrochloride, with a buffering agent—Capsules and Injection | A disease or condition specified in this column in relation to Chlortetracycline Capsules except herpes zoster ophthalmicus |
Rolitetracycline............... | |
Tetracycline Granules........... | |
Tetracycline Paediatric Drops...... |
|
Tetracycline Oral Suspension...... |
|
Tetracycline with a buffering agent—Paediatric Drops |
|
Tetracycline with a buffering agent—Oral Suspension |
|
| Broad spectrum antibiotic therapy of premature infants, of patients under steroid therapy or of cases complicated by intestinal moniliasis |
Tetracycline with a buffering agent and Amphotericin B | |
A second or repeated course of broad spectrum antibiotic therapy for a disease or condition specified in this column in relation to Chlortetracycline Capsules except herpes zoster ophthalmicus | |
Tetracycline with a buffering agent and Nystatin | |
| |
|
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
Thiambutosine Tablets, B.P........ | Hansen’s disease |
| Any disease or condition in a pensioner |
| Any disease or condition in a patient receiving treatment in or at an approved hospital |
| With the written authority of the Director-General— |
| Late-stage malignancy |
| Radiation sickness |
Thioridazine Tablets, B.P......... | With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
Thioridazine................. | |
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine Hydrochloride, Thioridazine Hydrochloride, Amitriptyline Hydrochloride or Imipramine Hydrochloride |
Thyrotrophin................. | Any disease in or condition in a patient receiving treatment in or at an approved hospital |
Tragacanth (Gum Karaya)........ | Ileostomy or colostomy conditions |
Tretamine................... | Malignant lymphoma and related conditions |
Triamcinolone................ | With the written authority of the Director-General, a disease or condition specified in this column in relation to Prednisolone Tablets |
Trifluoperazine Tablets, B.P....... | Any disease or condition in a pensioner |
| Any disease or condition in a patient receiving treatment in or at an approved hospital |
| With the written authority of the Director-General— |
| Late-stage malignancy |
| Radiation sickness |
| With the written authority of the Director-General, the treatment of a mental disorder in a person who has been discharged from an approved hospital at which he received treatment for a mental disorder and who is living in a place remote from an approved hospital |
| The treatment of a mental disorder in a person who has, after treatment for a mental disorder, been discharged from an approved hospital if a medical officer of the hospital gives a certificate certifying that that person received treatment at the hospital and may require further treatment with Chlorpromazine Hydrochloride, Trifluoperazine Hydrochloride, Thioridazine Hydrochloride, Amitriptyline Hydrochloride or Imipramine Hydrochloride |
Trimetaphan Injection, B.P........ | Hypotensive for anaesthesia |
Vadrine.................... | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Vasopressin Nasal Spray......... | Diabetes insipidus |
Velactin.................... | With the written authority of the Director-General— |
| Galactosaemia |
| Lactose intolerance |
| Milk allergy in children under the age of four years |
Fifth Schedule—continued
Pharmaceutical Benefits | Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act |
Vinblastine Sulphate........... | Hodgkin’s disease |
Viomycin Sulphate............ | Any disease or condition in a patient receiving treatment in or at an approved hospital |
Viomycin Sulphate Injection, B.P. |
|
| Tuberculosis |
Viomycin Sulphate with Viomycin Pantothenate |
|
Vitamin A with Aneurine Hydro- |
|
chloride, Riboflavine, Nicotinamide, Ascorbic Acid and Vitamin D | Any disease or condition in a pensioner |
_________________
By Authority: A. J. Arthur, Commonwealth Government Printer, Canberra.